NCAPG2

Across TCGA pan-cancer cohorts, NCAPG2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NCAPG2 data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher NCAPG2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated NCAPG2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, LUAD, and KIRC are the cancer types where NCAPG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.977	0.612	.001	24	view →
LUAD	OS	Median	II,III,IV	0.068	0.709	<.001	24	view →
KIRC	DFS	Median	All	0.127	0.865	<.001	12	view →
LIHC	OS	Median	All	0.164	0.704	.025	6	view →
LUSC	DFS	Median	All	0.377	0.649	.044	2	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NCAPG2–UCEC (DFS)

Open the UCEC breakdown →